<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-116456</identifier>
<setSpec>2253-654x</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Complete hormonal and metabolic response after iodine-131 metaiodobenzylguanidine treatment in a patient diagnosed of malignant pheochromocytoma</dc:title>
<dc:description xml:lang="en">Radiolabeled metaiodobenzylguanidine is an analogue of norepinephrine used to localize tumors that express the neurohormone transporters, specifically those derived from the neural crest having a neuroendocrine origin. It is also used to treat non-surgical metastases derived from them. A review of the literature revealed symptomatic improvements associated to a decrease in hormone levels in a significant percentage of patients after 131I-MIBG treatment. However, complete tumor remission has been described only in very few cases and hardly ever when bone metastases exist. We present a case of a patient diagnosed of malignant pheochromocytoma who achieved complete hormonal and metabolic response after 131I-MIBG treatment (600 mCi) in spite of the presence of bone metastases (AU)</dc:description>
<dc:creator>Balsa Bretón, M. A</dc:creator>
<dc:creator>García Alonso, M. P</dc:creator>
<dc:creator>Castillejos Rodríguez, L</dc:creator>
<dc:creator>Ortega Valle, A</dc:creator>
<dc:creator>Penín González, J</dc:creator>
<dc:creator>Rodríguez Pelayo, E</dc:creator>
<dc:creator>Paniagua Correa, C</dc:creator>
<dc:creator>Mendoza Paulini, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La metayodobencilguanidina radiomarcada es un análogo de la norepinefrina que se utiliza en la localización de tumores que expresan transportadores de dicha neurohormona, especialmente los derivados de la cresta neural y de origen neuroendocrino, y en el tratamiento de sus metástasis cuando estas no son quirúrgicas. En la literatura revisada se encuentran mejorías sintomáticas, asociadas a un descenso de los niveles hormonales, en un porcentaje no despreciable de casos tras el tratamiento con 131I-MIBG. Sin embargo, la remisión tumoral completa se ha descrito en muy pocas ocasiones y casi nunca en presencia de metástasis óseas. Presentamos un caso de feocromocitoma maligno que tras el tratamiento con 131I-MIBG (600 mCi) alcanzó una respuesta hormonal y metabólica completa a pesar de la existencia de metástasis óseas (AU)</dc:description>
<dc:source>Rev. esp. med. nucl. imagen mol. (Ed. impr.);32(6): 390-393, nov.-dic. 2013. tab, ilus</dc:source>
<dc:identifier>ibc-116456</dc:identifier>
<dc:title xml:lang="es">Respuesta hormonal y metabólica completa tras el tratamiento con yodo-131 metayodobencilguanidina en un caso de feocromocitoma maligno</dc:title>
<dc:subject>^d24339^s22045</dc:subject>
<dc:subject>^d10868^s29166</dc:subject>
<dc:subject>^d24338^s22045</dc:subject>
<dc:subject>^d33386^s22073</dc:subject>
<dc:subject>^d10868^s22012</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9871^s22048</dc:subject>
<dc:subject>^d24339^s22074</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d22935^s22045</dc:subject>
<dc:subject>^d9871^s22045</dc:subject>
<dc:subject>^d24338^s22039</dc:subject>
<dc:subject>^d22935^s22039</dc:subject>
<dc:subject>^d24339^s22039</dc:subject>
<dc:type>article</dc:type>
<dc:date>201312</dc:date>
</metadata>
</record>
</ibecs-document>
